Author:
Popova V. O.,Muslimova E. F.,Rebrova T. Yu.,Archakov E. A.,Batalov R. E.,Afanasiev S. A.
Reference26 articles.
1. Mareev, Yu.V., Polyakov, D.S., Vinogradova, N.G., et al., Epidemiology of atrial fibrillation in a representative sample from the European part of the Russian Federation: analysis of EPOCH-CHF study, Kardiologiya, 2022, vol. 62, no. 4, pp. 12—19. https://doi.org/10.18087/cardio.2022.4.n1997
2. Hindricks, G., Potpara, T., Dagres, N., et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, Eur. Heart J., 2020, vol. 42, no. 5, pp. 373—498. https://doi.org/10.1093/eurheartj/ehaa612
3. Afanas’ev, S.A., Rebrova, T.Y., Muslimova, E.F., and Borisova, E.V., Association of polymorphic variants of ADRB1 gene with contractile myocardial dysfunction and erythrocyte adrenoreactivity in patients with rhythm disorders, Ross. Kardiol. Zh., 2019, vol. 24, no. 7, pp. 47—52. https://doi.org/10.15829/1560-4071-2019-7-47-52
4. Afanas’ev, S.A., Lishmanov, Yu.B., Kondrat’ev, B.Yu., et al., Pharmacological evidence for myocardial adrenoreactivity disturbance under conditions of chronic coronary ischemia, Hum. Physiol., 1997, vol. 23, no. 5, pp. 563—566.
5. Barnes, P.J., β2–Agonists, anticholinergics, and other nonsteroid drugs, in Clinical Respiratory Medicine, Elsevier, 2008, Chapter 36, 3rd ed., pp. 471—482. https://doi.org/10.1016/B978-032304825-5.10036-4